Evidence map›Paper›PMID 38400849›Full record

ReviewMolecular biology reports2024

Therapeutic potency of A1 adenosine receptor antagonists in the treatment of cardiovascular diseases, current status and perspectives.

Amirhossein Bahreyni, Nikoo Saeedi, Abdulridha Mohammed Al-Asady, Atena Soleimani, Elnaz Ghorbani, Majid Khazaei, Maryam Alaei, Reyhane Hanaei, Mikhail Ryzhikov, Amir Avan and 1 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular biology reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Betaine Alters the Interplay of the Adenosine andInternational journal of molecular sciences · 2026
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 3 countries.

Amirhossein BahreyniDepartment of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Nikoo SaeediStudent Research Committee, Islamic Azad University, Mashhad Branch, Mashhad, Iran.
Abdulridha Mohammed Al-AsadyDepartment of Medical Sciences, Faculty of Nursing, University of Warith Al-Anbiyaa, Karbala, Iraq.
Atena SoleimaniDepartment of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Elnaz GhorbaniDepartment of Medical Microbiology and virology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Majid KhazaeiDepartment of Medical Physiology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Maryam AlaeiDepartment of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Reyhane HanaeiMetabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Mikhail RyzhikovSchool of Medicine, Saint Louis University, St. Louis, MO, USA.
Amir AvanMetabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. avana@mums.ac.ir.
Seyed Mahdi HassanianDepartment of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. hasanianmehrm@mums.ac.ir.ORCID http://orcid.org/0000-0001-6172-6225
Mashhad University of Medical Sciences · IRIslamic Azad University, Mashhad · IRSaint Louis University · US

Funding

National Institute for Medical Research Development 950852
6 · The paper itself

Abstract

backgroundCardiomyocytes form, transport, and metabolize the omnipresent metabolite adenosine. Depending upon the adenosine concentrations and the pharmacological properties of receptor subtypes, adenosine exerts (patho)physiological responses in the cardiovascular system. The objective of this review is to present different protective mechanisms of A1-adenosine receptor inhibitors in cardiovascular diseases. METHODS AND

resultsLiterature references were collected and sorted using relevant keywords and key phrases as search terms in scientific databases such as Web of Science, PubMed and Google Scholar. A1 adenosine receptor regulates free fatty acid metabolism, lipolysis, heart rate, blood pressure, and cardiovascular toxicity. The evidence clearly supporting the therapeutic potency of pharmacological A1 adenosine receptors agonists and antagonists in modulating cardiovascular risk factor parameters and treatment of cardiovascular diseases.

conclusionThis review summarizes the protective role of pharmacological A1-adenosine receptor regulators in the pathogenesis of cardiovascular diseases for a better management of cardiovascular diseases.

Indexed as

Cardiovascular DiseasesPurinergic P1 Receptor AntagonistsAdenosineBlood PressureHumansReceptors, Purinergic P1AdenosinePurinergic P1 Receptor AntagonistsReceptors, Purinergic P1A1 adenosine receptorCardiovascular diseasesPharmacological inhibitors

Identifiers

PMID38400849
OpenAlexW4392131344

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.